92
Participants
Start Date
March 8, 2018
Primary Completion Date
August 29, 2024
Study Completion Date
August 29, 2024
BMS-986258
Specified dose on specified days
Nivolumab
Specified dose on specified days
rHuPH20
Specified dose on specified days
Local Institution - 0013, Westmead
Local Institution - 0015, Melbourne
Local Institution - 0005, Pittsburgh
Local Institution - 0002, Germantown
Local Institution - 0016, Cincinnati
Local Institution - 0010, Grand Rapids
University Of Iowa Hospitals And Clinics, Iowa City
Local Institution - 0007, Aurora
Local Institution - 0004, Los Angeles
Local Institution - 0006, Los Angeles
Local Institution - 0008, Chuo-ku
Local Institution - 0009, Kobe
Local Institution - 0018, Ann Arbor
Local Institution - 0012, Lebanon
Local Institution - 0014, Edmonton
Local Institution - 0019, Vancouver
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY